MA29259B1 - 2-phénylindoles en tant qu'antagonistes du récepteur de la prostaglandine d2 - Google Patents
2-phénylindoles en tant qu'antagonistes du récepteur de la prostaglandine d2Info
- Publication number
- MA29259B1 MA29259B1 MA30150A MA30150A MA29259B1 MA 29259 B1 MA29259 B1 MA 29259B1 MA 30150 A MA30150 A MA 30150A MA 30150 A MA30150 A MA 30150A MA 29259 B1 MA29259 B1 MA 29259B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutically acceptable
- xvi
- urticaria
- solvate
- inflammation
- Prior art date
Links
- 102000009389 Prostaglandin D receptors Human genes 0.000 title 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 208000024780 Urticaria Diseases 0.000 abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010002199 Anaphylactic shock Diseases 0.000 abstract 1
- 206010053582 Bronchopneumopathy Diseases 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 abstract 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 201000008736 Systemic mastocytosis Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 150000004678 hydrides Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000007803 itching Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010036784 proctocolitis Diseases 0.000 abstract 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 238000006748 scratching Methods 0.000 abstract 1
- 230000002393 scratching effect Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64730705P | 2005-01-26 | 2005-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29259B1 true MA29259B1 (fr) | 2008-02-01 |
Family
ID=36282872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30150A MA29259B1 (fr) | 2005-01-26 | 2007-08-17 | 2-phénylindoles en tant qu'antagonistes du récepteur de la prostaglandine d2 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20070265278A1 (enExample) |
| EP (1) | EP1844011A1 (enExample) |
| JP (1) | JP2008528606A (enExample) |
| KR (1) | KR20070110277A (enExample) |
| CN (1) | CN101146770A (enExample) |
| AR (1) | AR054726A1 (enExample) |
| AU (1) | AU2006209213A1 (enExample) |
| BR (1) | BRPI0607079A2 (enExample) |
| CA (1) | CA2595728A1 (enExample) |
| CR (1) | CR9214A (enExample) |
| DO (1) | DOP2006000016A (enExample) |
| GT (1) | GT200600030A (enExample) |
| IL (1) | IL184816A0 (enExample) |
| MA (1) | MA29259B1 (enExample) |
| MX (1) | MX2007008277A (enExample) |
| NO (1) | NO20074336L (enExample) |
| PA (1) | PA8661201A1 (enExample) |
| PE (1) | PE20060878A1 (enExample) |
| RU (1) | RU2007132166A (enExample) |
| SG (1) | SG158918A1 (enExample) |
| TN (1) | TNSN07251A1 (enExample) |
| TW (1) | TW200639151A (enExample) |
| UY (1) | UY29346A1 (enExample) |
| WO (1) | WO2006081343A1 (enExample) |
| ZA (1) | ZA200705449B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2066628E (pt) * | 2006-07-25 | 2010-12-31 | Sanofi Aventis | 2-fenil-indoles como antagonistas do receptor da prostaglandina d2 |
| KR101411820B1 (ko) | 2006-08-07 | 2014-06-24 | 액테리온 파마슈티칼 리미티드 | (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체 |
| WO2008061006A1 (en) * | 2006-11-10 | 2008-05-22 | Wyeth | Substituted indan-2-yl, tetrahydronaphthalen-2-yl, or dihydr0-2h-chr0men-3-yl arylsulfonamides and methods of their use |
| WO2009061730A2 (en) * | 2007-11-05 | 2009-05-14 | Array Biopharma Inc. | 4-heteroaryl-substituted phenoxyphenylacetic acid |
| PL2558447T3 (pl) | 2010-03-22 | 2015-03-31 | Idorsia Pharmaceuticals Ltd | Pochodne 3-(heteroaryloamino)-1,2,3,4-tetrahydro-9h-karbazolu i ich zastosowanie jako modulatorów receptora prostaglandyny D2 |
| WO2012046653A1 (ja) * | 2010-10-06 | 2012-04-12 | 株式会社クレハ | アミン系化合物とその用途 |
| US9096595B2 (en) | 2011-04-14 | 2015-08-04 | Actelion Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators |
| EP2548863A1 (en) * | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
| EP2762141A4 (en) * | 2011-09-29 | 2015-03-25 | Shionogi & Co | THERAPEUTIC PHARMACEUTICAL PRODUCT AGAINST ALLERGIC RHINITIS COMPRISING A PGD2 ANTAGONIST AND A HISTAMINE ANTAGONIST |
| BR112014015081A8 (pt) | 2011-12-21 | 2017-06-13 | Actelion Pharmaceuticals Ltd | derivados heterocíclicos e seu uso como moduladores do receptor d2 de prostaglandina |
| JP6127135B2 (ja) | 2012-07-05 | 2017-05-10 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | １−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用 |
| EP3382391A1 (en) | 2012-10-24 | 2018-10-03 | NYU Winthrop Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| JP6168520B2 (ja) * | 2013-09-17 | 2017-07-26 | 国立大学法人 千葉大学 | インドール化合物、ｄｐプロスタノイド受容体アンタゴニスト、それを用いた薬剤、及びｄｐプロスタノイド受容体アンタゴニストの使用。 |
| JP2015089886A (ja) * | 2013-11-06 | 2015-05-11 | 国立大学法人名古屋大学 | 嵩高い置換基を有する化合物を用いた植物成長調整剤 |
| HUE039614T2 (hu) | 2014-03-17 | 2019-01-28 | Idorsia Pharmaceuticals Ltd | Azaindol-ecetsav-származékok és prosztaglandin D2 receptor modulátorokként történõ alkalmazásuk |
| KR20160133536A (ko) | 2014-03-18 | 2016-11-22 | 액테리온 파마슈티칼 리미티드 | 아자인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 이의 용도 |
| MX379014B (es) | 2015-09-15 | 2025-03-10 | Idorsia Pharmaceuticals Ltd | Formas cristalinas. |
| KR20200109293A (ko) | 2017-09-13 | 2020-09-22 | 프로제너티, 인크. | 자간전증 바이오마커 및 관련된 시스템 및 방법 |
| US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| CN113173877B (zh) * | 2020-10-30 | 2023-10-27 | 江西师范大学 | 吲哚乙酰基亚氨基砜系列化合物及其制备方法 |
| CN115925606B (zh) * | 2023-01-05 | 2023-10-13 | 宁夏医科大学 | 一种5-（3-（磺酰胺基）苯基）-1h-吡咯-2-羧酸衍生物及其制备方法和应用 |
| CN117599052A (zh) * | 2023-07-25 | 2024-02-27 | 温州医科大学附属眼视光医院 | Ptgds的抑制剂在制备治疗白内障药物上的应用 |
| US12220411B1 (en) | 2023-07-25 | 2025-02-11 | The Eye Hospital Of Wenzhou Medical University | Application of PTGDS inhibitor in preparation of drug for treating cataracts |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2135160A1 (en) * | 1992-05-08 | 1993-11-25 | Masatoshi Inai | Indole derivative |
| FR2751966B1 (fr) * | 1996-08-01 | 1998-10-30 | Union Pharma Scient Appl | Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique |
| US6500853B1 (en) * | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| JP2004024655A (ja) * | 2002-06-27 | 2004-01-29 | Aruze Corp | 遊技機 |
| WO2004078719A1 (ja) * | 2003-03-06 | 2004-09-16 | Ono Pharmaceutical Co., Ltd. | インドール誘導体化合物およびその化合物を有効成分とする薬剤 |
| SE0301569D0 (sv) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| EP1771169A1 (en) * | 2004-07-14 | 2007-04-11 | PTC Therapeutics, Inc. | Methods for treating hepatitis c |
| US7868037B2 (en) * | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
-
2006
- 2006-01-20 DO DO2006000016A patent/DOP2006000016A/es unknown
- 2006-01-24 PE PE2006000105A patent/PE20060878A1/es not_active Application Discontinuation
- 2006-01-25 WO PCT/US2006/002736 patent/WO2006081343A1/en not_active Ceased
- 2006-01-25 AR ARP060100278A patent/AR054726A1/es not_active Application Discontinuation
- 2006-01-25 CA CA002595728A patent/CA2595728A1/en not_active Abandoned
- 2006-01-25 RU RU2007132166/04A patent/RU2007132166A/ru not_active Application Discontinuation
- 2006-01-25 MX MX2007008277A patent/MX2007008277A/es not_active Application Discontinuation
- 2006-01-25 AU AU2006209213A patent/AU2006209213A1/en not_active Abandoned
- 2006-01-25 GT GT200600030A patent/GT200600030A/es unknown
- 2006-01-25 KR KR1020077017292A patent/KR20070110277A/ko not_active Withdrawn
- 2006-01-25 CN CNA2006800097886A patent/CN101146770A/zh active Pending
- 2006-01-25 SG SG201000540-3A patent/SG158918A1/en unknown
- 2006-01-25 BR BRPI0607079-5A patent/BRPI0607079A2/pt not_active IP Right Cessation
- 2006-01-25 JP JP2007553221A patent/JP2008528606A/ja active Pending
- 2006-01-25 EP EP06719551A patent/EP1844011A1/en not_active Withdrawn
- 2006-01-26 TW TW095102967A patent/TW200639151A/zh unknown
- 2006-01-26 PA PA20068661201A patent/PA8661201A1/es unknown
- 2006-01-26 UY UY29346A patent/UY29346A1/es unknown
-
2007
- 2007-06-28 CR CR9214A patent/CR9214A/es not_active Application Discontinuation
- 2007-07-03 TN TNP2007000251A patent/TNSN07251A1/en unknown
- 2007-07-04 ZA ZA200705449A patent/ZA200705449B/xx unknown
- 2007-07-24 IL IL184816A patent/IL184816A0/en unknown
- 2007-07-25 US US11/782,890 patent/US20070265278A1/en not_active Abandoned
- 2007-08-17 MA MA30150A patent/MA29259B1/fr unknown
- 2007-08-24 NO NO20074336A patent/NO20074336L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1844011A1 (en) | 2007-10-17 |
| SG158918A1 (en) | 2010-02-26 |
| AR054726A1 (es) | 2007-07-11 |
| MX2007008277A (es) | 2007-09-07 |
| CR9214A (es) | 2007-11-23 |
| PA8661201A1 (es) | 2006-09-08 |
| PE20060878A1 (es) | 2006-10-18 |
| TNSN07251A1 (en) | 2008-12-31 |
| JP2008528606A (ja) | 2008-07-31 |
| KR20070110277A (ko) | 2007-11-16 |
| GT200600030A (es) | 2006-09-27 |
| RU2007132166A (ru) | 2009-03-10 |
| CN101146770A (zh) | 2008-03-19 |
| CA2595728A1 (en) | 2006-08-03 |
| ZA200705449B (en) | 2009-01-28 |
| NO20074336L (no) | 2007-10-23 |
| UY29346A1 (es) | 2006-08-31 |
| AU2006209213A1 (en) | 2006-08-03 |
| IL184816A0 (en) | 2007-12-03 |
| TW200639151A (en) | 2006-11-16 |
| DOP2006000016A (es) | 2006-07-31 |
| US20070265278A1 (en) | 2007-11-15 |
| BRPI0607079A2 (pt) | 2009-08-04 |
| WO2006081343A1 (en) | 2006-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29259B1 (fr) | 2-phénylindoles en tant qu'antagonistes du récepteur de la prostaglandine d2 | |
| MA30409B1 (fr) | Amino-pyrimidine 2,6-substituee-4-mono-substituee en tant qu'antagoniste du recepteur de la prostaglandine d2. | |
| MA30643B1 (fr) | 2-phenylindoles en tant qu'antagonistes du recepteur de la prostaglandine d2. | |
| MA30005B1 (fr) | Sel dihydrogenophosphate d'un antagoniste du recepteur de la prostaglandine d2 | |
| JP3935201B2 (ja) | 神経弛緩薬ａｆｓとしてのｎ−置換されたアザビシクロアルカン誘導体 | |
| MA29335B1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
| US9580400B2 (en) | Cannabinergic nitrate esters and related analogs | |
| WO2003106452A3 (en) | Antagonists of melanin concentrating hormone receptor | |
| ZA200503693B (en) | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | |
| WO2004002948A1 (ja) | アミド化合物およびその医薬用途 | |
| TNSN05174A1 (fr) | Derives de 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazine-2-yl)-benzamide servant d'inhibiteurs de p2x7 pour le traitement de maladies inflammatoires | |
| MA29692B1 (fr) | Derives de la xanthine en tant qu'agonistes selectifs du hm74a | |
| MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
| MA27647A1 (fr) | Antagonistes de ccr5 utiles comme agents therapeutiques | |
| MA29772B1 (fr) | Benzimidazoles substitues et procedes de preparation | |
| US8138205B2 (en) | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 | |
| MA27926A1 (fr) | Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1 | |
| BRPI0516482A (pt) | 2, 6-substituìda-4-monossubstituìda-amino-pirimidina como antagonistas receptor de prostaglandina d2 | |
| CN1265649A (zh) | 作为mcp－1受体拮抗剂的吲哚衍生物 | |
| MA30289B1 (fr) | Dérivés d'amines | |
| HU207946B (en) | Process for producing eye-pressure-diminishing pharmaceutical compositions containing /2-imidazolin-2-yl-amino/-quinoxaline derivatives | |
| JP2004532229A (ja) | 脂肪酸アミド加水分解酵素阻害剤 | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| CN1116928A (zh) | 眼用组合物 | |
| JP2007530601A5 (enExample) |